Armistice Capital, LLC Acquires 9.99% Stake in Dogwood Therapeutics, Inc. (DWTX)

Armistice Capital, LLC and its managing member, Steven Boyd, have filed a Schedule 13G indicating a new substantial position in Dogwood Therapeutics, Inc. (DWTX). As of March 31, 2026, the reporting persons beneficially own 3,343,120 shares of common stock, representing a 9.99% stake in the company. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Under the terms of their Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over the securities. Steven Boyd, by virtue of his position as managing member of Armistice Capital, is also deemed to have beneficial ownership. The filing specifies that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This position marks a significant entry for the investment firm into Dogwood Therapeutics, reaching the common 9.99% ownership threshold often utilized by institutional investors.